Cosmos Holdings Announces Strategic R&D Partnership with Cloudpharm P.C. to Study the Human Gastrointestinal Microbiome and Launch Related Products Targeting on Obesity and Other Gut-Related Disorders - Seite 2

Greg Siokas, Chief Executive Officer of Cosmos Holdings, commented, "Collaborating with Cloudpharm is an important milestone in developing new IP products targeting major health disorders such as obesity, diabetes, cancer and other prevalent diseases globally. The gut microbiome plays an important role in human health by helping control digestion, as well as contributing to the overall functioning of the immune system and other important aspects of health. An imbalance of unhealthy and healthy microbes in the intestines may contribute to weight gain, high blood sugar, high cholesterol and other disorders. Cloudpharm is an ideal strategic partner, as their expertise in the field of drug discovery, the wide network of collaborators and the efficient cloud and IT resources, is expected to help us advance high quality pharmaceutical and nutraceutical products. We look forward to launching our joint project with Cloupharm to evaluate the effect of the microbiome has on obesity and reporting results of our upcoming trial as they become available."

About Cloudpharm P.C.

Cloudpharm is a bio-pharmaceutical R&D company founded in 2016 and established in Athens, Greece. It entered the Eurobank-Corralia enter-go-grow incubator for startups in 2015 and has been selected as one of the three Greek startups to join DMZ Toronto. Its core activities focus on the discovery of bioactive compounds with emphasis on natural products, with the aim of developing new medicines, cosmetics and nutraceuticals. Utilizing cloud based proprietary chemoinformatic tools Cloudpharm offers specialized services in the fields of drug discovery, drug repurposing and nutraceuticals. It is a knowledge-intense company, and its team is comprised of scientists with extensive research experience in pharmaceutical R&D and computer science. Cloudpharm maintains an extensive national and European network of academic and industrial partners such as the National Hellenic Research Foundation, Autonomous University of Barcelona LMC, National Technical University of Athens, University of West Attica, Athens Medical School LRMS and others. During the last five years, Cloudpharm has received funding through Greek national and EC competitive research programs and in 2022 started a new Horizon EC project as part of the consortium ENVIROMED for the development of a next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact.